Sabra Health Care REIT (NASDAQ:SBRA - Get Free Report) will post its quarterly earnings results after the market closes on Thursday, October 31st. Analysts expect Sabra Health Care REIT to post earnings of $0.35 per share for the quarter. Sabra Health Care REIT has set its FY24 guidance at $1.39-1.42 EPS and its FY 2024 guidance at 1.360-1.390 EPS.Investors interested in registering for the company's conference call can do so using this link.
Sabra Health Care REIT (NASDAQ:SBRA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The real estate investment trust reported $0.10 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.24). The business had revenue of $176.14 million during the quarter, compared to analysts' expectations of $166.54 million. Sabra Health Care REIT had a net margin of 7.83% and a return on equity of 1.87%. Sabra Health Care REIT's revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.34 earnings per share. On average, analysts expect Sabra Health Care REIT to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of SBRA opened at $18.99 on Thursday. The business's 50 day moving average is $17.76 and its 200 day moving average is $15.91. The company has a current ratio of 4.27, a quick ratio of 4.27 and a debt-to-equity ratio of 0.89. Sabra Health Care REIT has a 12-month low of $12.83 and a 12-month high of $19.32. The company has a market capitalization of $4.45 billion, a PE ratio of 90.43, a price-to-earnings-growth ratio of 2.68 and a beta of 1.26.
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Stockholders of record on Monday, August 19th were given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 6.32%. The ex-dividend date was Monday, August 19th. Sabra Health Care REIT's payout ratio is currently 571.43%.
SBRA has been the subject of a number of research reports. Truist Financial upped their target price on shares of Sabra Health Care REIT from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Citigroup upgraded Sabra Health Care REIT from a "neutral" rating to a "buy" rating and raised their price objective for the company from $17.00 to $20.00 in a research report on Friday, September 13th. Wells Fargo & Company upgraded Sabra Health Care REIT from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $16.00 to $20.00 in a research report on Tuesday, October 1st. Finally, Scotiabank raised their price target on Sabra Health Care REIT from $17.00 to $18.00 and gave the company a "sector perform" rating in a report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Sabra Health Care REIT presently has a consensus rating of "Moderate Buy" and an average target price of $18.38.
View Our Latest Analysis on Sabra Health Care REIT
As of September 30, 2023, Sabra's investment portfolio included 377 real estate properties held for investment (consisting of (i) 240 Skilled Nursing/Transitional Care facilities, (ii) 43 senior housing communities (Senior Housing - Leased), (iii) 61 senior housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed), (iv) 18 Behavioral Health facilities and (v) 15 Specialty Hospitals and Other facilities), 12 investments in loans receivable (consisting of two mortgage loans and 10 other loans), five preferred equity investments and two investments in unconsolidated joint ventures.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sabra Health Care REIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sabra Health Care REIT wasn't on the list.
While Sabra Health Care REIT currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.